Sapient Capital’s Exact Sciences EXAS Stock Holding History

Sapient Capital’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,563	Closed	-$246K	–	366
2024 Q1	$246K	Sell	3,563 -253	-7%	-$16K	0.01%	327
2023 Q4	$282K	Buy	+3,816	New	+$250K	0.01%	304

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Sapient Capital's EXAS Position: Q2 2024 in Review

Sapient Capital sold out of Exact Sciences (EXAS) in Q2 2024, closing a stake of 3,563 shares — an estimated $246K sold.

Sapient Capital first reported a position in EXAS in Q4 2023 and held it in 2 quarters. The position peaked at $282K in Q4 2023. 543 funds tracked by Wall St. Rank hold EXAS as of Q2 2024.

Sapient Capital reported no remaining Exact Sciences position as of Q2 2024 after selling out during the quarter.
Sapient Capital sold 3,563 Exact Sciences shares in Q2 2024, an estimated $246K.
Sapient Capital first reported a position in Exact Sciences in Q4 2023 and held it in 2 quarters.
Sapient Capital's Exact Sciences position peaked at $282K in Q4 2023.
543 funds tracked by Wall St. Rank held Exact Sciences as of Q2 2024.

Based on Sapient Capital's 13F filing for Q2 2024, filed 15 Jul 2024.